Post-earnings recap
Reported
Wed, May 11, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported an EPS of $-0.13, which was better than expected. However, there was no revenue reported, leading to a slight decline in stock price by 0.83%. Investors may be cautious due to the lack of revenue details and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | +7.14% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.